iRhythm Technologies (IRTC) Peer Comparison

$119.66

$3.33 (2.86%)

As on 28-Aug-2026 13:35EDT

Market cap

$4,236 Mln

Revenue (TTM)

$825 Mln

P/E Ratio

--

P/B Ratio

22.7

Div. Yield

0 %

Edit

	iRhythm Technologies (IRTC)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Market cap ($ Mln)	4,236	12,753	10,906	10,222	9,762
Revenue ($ Mln)	825	1,505	613	785	2,589
Net Profit ($ Mln)	-13.95	160.59	-188.05	41.54	222.40
Net Margin (%)	-1.69	10.67	-30.68	5.29	8.59
RoE (%)	-8.23	10.86	-28.10	1.97	3.04
Price to Earnings	--	79.35	--	251.57	44.47
Price-To-Book	22.68	8.41	16.38	4.84	1.26

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	iRhythm Technologies (IRTC)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Operating Revenue	825.34	1,504.87	612.84	785.10	2,589.30
Cost of Revenue	235.60	483.98	127.96	384.30	1,245.50
Gross Profit	527.25	942.44	393.22	347.62	1,343.60
Operating Expenses	599.37	833.56	565.37	335.50	1,108.90
Operating Profit (EBIT)	-9.63	187.34	-80.49	65.30	235.00
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-12.98	203.83	-192.83	52.15	350.40
Provision for Tax	0.97	43.24	-4.79	10.61	128.00
Profit after Tax (Net Income)	-13.95	160.59	-188.05	41.54	222.40
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	93.19	0.00	0.00	0.00

Liabilities ($ Mln)

	iRhythm Technologies (IRTC)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Shareholder's Funds	185.98	1,530.77	682.49	2,112.03	7,173.90
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	711.35	210.18	135.71	705.49	2,116.80
Current Liabilities	195.58	233.78	102.33	132.66	961.30
Total Liabilities	1,020.04	1,826.52	893.49	2,949.70	10,576.50

Assets ($ Mln)

	iRhythm Technologies (IRTC)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Non-Current Assets	337.47	630.60	404.74	1,749.63	7,231.50
Current Assets	755.95	1,344.12	515.78	1,200.55	3,020.50
Total Assets	1,020.04	1,826.52	893.49	2,949.70	10,576.50
Total Debt*	727.35	212.71	102.84	690.94	1,203.70
Net Current Assets	559.86	1,110.35	413.45	1,067.90	2,059.20

Cashflow ($ Mln)

	iRhythm Technologies (IRTC)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Cash From Operating Activities	80.86	238.66	-46.34	117.42	532.20
Cash Flow from Investing Activities	-277.06	-404.59	-77.61	-298.47	-189.70
Cash from Financing Activities	12.61	26.53	11.89	-15.21	-283.20
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	iRhythm Technologies (IRTC)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
ROCE (%)	-5.21	11.76	-22.53	1.79	8.98
ROE (%)	-8.23	10.86	-28.10	1.97	3.04
ROA (%)	-1.17	7.95	-18.00	1.36	2.02
EBIT Margin (%)	-0.33	13.63	-30.58	9.87	-5.99
Net Margin (%)	-1.69	10.67	-30.68	5.29	8.59
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	iRhythm Technologies (IRTC)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Revenue Growth (%)	25.58	17.55	41.55	16.49	1.37
EBIT Growth (%)	96.55	17.49	-116.42	920.91	-131.06
Net Profit Growth (%)	84.91	8.72	-102.66	400.42	-30.32
EPS Growth (%)	85.19	8.12	-96.88	394.30	-29.66
Book Value Growth (%)	74.48	17.33	-12.65	2.16	2.19

Valuation Ratios

	iRhythm Technologies (IRTC)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Price / Earnings	-132.76	68.93	-34.59	189.42	--
Price / Book Value	38.72	8.58	9.90	4.40	--
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-1,528.84	53.25	-43.50	55.90	--
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	iRhythm Technologies (IRTC)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Debt to Equity	3.50	0.00	0.00	0.26	0.11
Short term debt to equity ratio	0.10	0.01	0.00	0.01	0.06
Current Ratio	3.87	5.75	5.04	9.05	3.14
Quick Ratio	3.75	3.86	4.46	7.64	2.33
Interest Coverage	0.02	157.91	-38.31	3.36	8.18

Operating Efficiency Ratios

	iRhythm Technologies (IRTC)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Debtors to sales (%)	10.21	12.65	22.67	20.09	17.06
Asset Turnover	0.69	0.74	0.59	0.26	0.24
Receivable days	38.05	46.54	60.95	72.41	65.39
Inventory Days	29.63	331.92	193.84	146.53	221.09
Payable days	7.87	26.16	60.19	29.05	37.02
Cash Conversion Cycle	59.80	352.30	194.60	189.88	249.46

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly